# Persistent Systems & NVIDIA Team Up to Accelerate AI Drug Discovery

URL: https://technosports.co.in/persistent-systems-nvidia-ai-drug-discovery/  
Published: 2026-03-17  
Updated: 2026-03-17  
Author: Hardik Dhamija

Finding new drugs is slow, expensive, and often fails late in the process — AI is about to change that. [Persistent Systems](https://www.persistent.com/) has announced a collaboration with NVIDIA to deploy AI-powered drug discovery solutions for the Healthcare and Life Sciences (HLS) industry, built on the NVIDIA BioNeMo platform. The centrepiece of this collaboration is **GenMolVS** — a Generative Molecules and Virtual Screening solution that can compress months-long experiments into days.

![Persistent Systems](https://technosports.co.in/wp-content/uploads/2026/03/Persistent-Systems-1-2-1024x538.jpg)
*Persistent Systems*

## Persistent x NVIDIA GenMolVS: Key Details

| Detail | Info |
| --- | --- |
| Solution Name | GenMolVS (Generative Molecules & Virtual Screening) |
| Partners | Persistent Systems & [NVIDIA](https://technosports.co.in/?s=NVIDIA) |
| Powered By | NVIDIA BioNeMo, NeMo Agent Toolkit, NIM Microservices |
| Models Used | NVIDIA Nemotron open models |
| Target Industry | Healthcare & Life Sciences / BioPharma |
| Key Use Case | Computational drug discovery, virtual screening |
| Infrastructure | NVIDIA AI Enterprise, accelerated compute, NIM microservices |
| Outcome | Months-long experiments compressed to days |

![](https://technosports.co.in/wp-content/uploads/2026/03/OpenAI-NVIDIA-2-3.jpg)
*Persistent Systems*

## What GenMolVS Actually Does

Early-stage drug discovery has always been a costly gamble — researchers run countless wet laboratory experiments hoping to find viable molecular candidates, with most failing at significant expense. GenMolVS flips that model. Rather than testing molecules in a lab first, it uses AI-driven molecular simulations to model the physical and chemical properties of molecules digitally, screening candidates virtually before a single experiment is run.

The agentic AI workflows built on NVIDIA NeMo enable continuous decisioning across virtual screening, candidate prioritisation, and experimental planning — translating simulations directly into informed lab strategies. Persistent’s EVP Ganesh Nathella put it plainly: the goal is to help BioPharma clients move from months-long experiments to AI-driven discovery in days without compromising on scientific rigour or compliance.

NVIDIA’s John Fanelli added that the industry is rapidly moving toward AI-driven computational research to meet urgent global demand for new therapies — and this collaboration puts production-grade tools directly into biopharma hands. Read more on AI in healthcare and enterprise tech at Technosports.

## FAQs

### **What is Persistent’s GenMolVS solution?**

An AI-powered Generative Molecules and Virtual Screening tool that simulates molecular behaviour digitally, enabling faster and more cost-effective drug discovery.

### **Which NVIDIA technologies power the Persistent GenMolVS solution?**

NVIDIA BioNeMo, NeMo Agent Toolkit, NIM microservices, Nemotron open models, and NVIDIA AI Enterprise infrastructure.